End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
14.59 MXN | 0.00% | +0.07% | +3.04% |
Apr. 24 | Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Mar. 13 | Genomma Lab Internacional, S.A.B. De C.V. Declares Cash Dividend | CI |
Summary
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- The company's attractive earnings multiples are brought to light by a P/E ratio at 11.51 for the current year.
- The company has a low valuation given the cash flows generated by its activity.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+3.04% | 820M | B+ | ||
+24.17% | 562B | B | ||
-6.33% | 358B | C+ | ||
+19.90% | 322B | B- | ||
+7.95% | 297B | C+ | ||
+13.45% | 219B | B+ | ||
+6.04% | 199B | B- | ||
-10.51% | 196B | A+ | ||
-12.26% | 149B | C+ | ||
-6.47% | 146B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- LAB B Stock
- Ratings Genomma Lab Internacional, S.A.B. de C.V.